Xigris meeting rescheduled

FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)